|
Press Releases |
|
 |
|
Wednesday, September 17, 2025 |
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). more info >> |
|
Friday, September 12, 2025 |
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the release of a concept movie and new content on the dedicated website for its "New Answers to Dementia" campaign, designed to increase corporate awareness. more info >> |
|
Monday, September 8, 2025 |
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. more info >> |
|
Thursday, September 4, 2025 |
|
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data on the selective orexin 2 receptor agonist (OX2R) E2086 and the latest findings on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO(R)) at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10. more info >> |
|
Wednesday, September 3, 2025 |
|
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. more info >> |
|
Monday, September 1, 2025 |
|
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIKTM, pronounced "I Click") for maintenance dosing. more info >> |
|
Friday, August 29, 2025 |
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (genericname, product name "Tazverik(R) Tablets 200 mg", "tazemetostat") for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
Monday, August 25, 2025 |
|
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the anti-amyloid beta (AB) monoclonal antibody "LEQEMBI(R)" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. more info >> |
|
Monday, August 18, 2025 |
|
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO(R) (brand name in China: "DAYVIGO(R)" generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
Thursday, July 31, 2025 |
|
Revenue of LEQEMBI(R) (Preliminary Basis) |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody "LEQEMBI(R)" (generic name: lecanemab) was JPY 23.1 billion for the first quarter of fiscal year 2025 (April 1, 2025 - June 30, 2025). more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Mitsubishi Motors Launches the All-New Eclipse Cross Electric Vehicle for the European Market
Sept 18, 2025 0:58 JST
|
|
|
Mitsubishi Motors to Begin Sales of All-New Delica Mini and eK Space in Japan in October
Sept 18, 2025 0:50 JST
|
|
|
Upgraded GR Corolla Set for Japan Launch
Sept 18, 2025 0:48 JST
|
|
|
Honda Koraidon Ride on Experience and Onboard Showrun to be Held at Honda Collection Hall
Sept 18, 2025 0:42 JST
|
|
|
Mitsubishi Motors Increases Investment Stake in Australian Automotive Financial Services Company to 19.93%
Sept 18, 2025 0:27 JST
|
|
|
MHI Is Awarded Contract for 20 Units of the Outer Vertical Target for the Divertor Used in the ITER in Southern France
Sept 18, 2025 0:16 JST
|
|
|
NTT and Mitsubishi Heavy Industries Achieved World's Highest Efficiency in Laser Wireless Power Transmission under Atmospheric Turbulence
Sept 18, 2025 0:00 JST
|
|
|
Galaxy Payroll Group Limited Granted Additional 180-Day Compliance Period by Nasdaq to Regain Minimum Bid Price Requirement
Sept 18, 2025 22:30 HKT/SGT
|
|
|
CGSI Reiterates 'Add' Rating on Modern Dental (03600.HK) with Raised Target Price of HK$6.88
Sept 18, 2025 16:30 HKT/SGT
|
|
|
Counterfeit Products Sold Online in Malaysia Threaten Halal Compliance, Consumer Health, and the E-Commerce Sector, Says Muslim Consumers Association (PPIM)
Sept 18, 2025 13:20 HKT/SGT
|
|
|
Dongwu Cement (00695.HK) Undergoes Major Transformation with Suzhou State Capital Takeover
Sept 18, 2025 08:30 HKT/SGT
|
|
|
GMG Launches First to Market Multi Language Global Graphene Enhanced Product Range for Distributors
Sept 17, 2025 19:39 HKT/SGT
|
|
|
Casa Minerals Inc Announces Advanced Ground IP Survey at the Arsenault Project
Sept 17, 2025 18:09 HKT/SGT
|
|
|
Definitive agreement to implement a joint mine plan between Los Bronces and Andina copper mines
Sept 17, 2025 18:57 JST
|
|
|
Open Doors to the Asian Market: Seoul Bio Hub-Celltrion Launches 'Global Open Innovation' for U.S. Startups
Sept 17, 2025 17:30 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|